AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, including conditions which qualify for Orphan drug status.
The company has a portfolio of product candidates derived from its Known Molecular Entity (KME™) approach to drug re-profiling and development and aims to bring its products to the market either directly or through out-licensing or other partnering arrangements.
AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
Rule 26 Disclosures
Visitors to this website may access those disclosures required by Rule 26 of the AIM and IEX Rules under “Corporate Governance” in the “Investors” section of this website, or by clicking here
